Purple Biotech has parked the two programs that once defined it as a clinical-stage oncology name and concentrated the remaining cash on a preclinical tri-specific antibody platform. Management has been explicit that further work on the CEACAM-blocking antibody and the dual resistance-pathway small molecule now depends on a partner or fresh outside capital. That is not a pause. It is a write-down of strategy: year-end results took a large impairment against those assets and redirected spend toward the masked engager franchise. The equity is no longer a Phase Two story. It is a cash-clock option on whether a still-untested platform attracts a collaborator before the runway ends.
The second-quarter print looks profitable only because warrant liabilities were marked down as the share price compressed. Operating reality is a small, steady cash burn against a shrinking cash pile. Cash and short-term deposits sat at $6.1 million at mid-year. That is below the year-end pile and above the current equity value. Adjusted net loss in the quarter was $1.2 million, essentially unchanged from a year earlier, which is the cleaner read than the reported profit. The market is pricing the platform at less than nothing and treating cash as already spoken for by future dilution.
The next several quarters resolve a single question. Does a collaborator or a financed first-in-human plan appear before the stated runway through the middle of next year is consumed by manufacturing, toxicology, and listing maintenance? If the answer is yes, the equity is a cheap call on a masked engager platform that has generated consistent preclinical signals. If the answer is no, the remaining cash is a bridge to another reverse-split and another raise.